ARQT Stock Price | Arcutis Biotherapeutics Inc P/E, Revenue, EPS, & Forecasts

Arcutis Biotherapeutics Inc • ARQT

ARQT current price

$15.19+396.36%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

+14.30%

+32.78%

+63.65%

+59.13%

+396.36%

MAX

-31.24%

About Arcutis Biotherapeutics Inc

Ticker

ARQT

Trading on

NASDAQ

ISIN

US03969K1088

Industry

Biotechnology

Sector

Healthcare

CEO

Todd Franklin Watanabe M.A.

Headquarters

3027 Townsgate Road, Westlake Village, CA, United States, 91361

Employees

296

Website

arcutis.com

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Metrics

BasicAdvanced

Market cap

$1.75B

P/E ratio

EPS

-$1.67

Dividend Yield

0.00%

Beta

1.19

Forward P/E ratio

EBIDTA

$-179M

Ex dividend date

Price & volume

Market cap

$1.75B

Average daily volume

2.3M

90-day return

63.65%

30-day return

32.78%

7-day return

14.30%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

12.65

Price to book

11.2

Earnings

EPS

-$1.67

EPS estimate (current quarter)

-$0.42

EPS estimate (next quarter)

-$0.36

EBITDA

$-179M

Revenues (TTM)

$139M

Revenues per share (TTM)

$1.23

Technicals

Beta

1.19

52-week High

$15.79

52-week Low

$2.99

50-day moving average

$10.80

200-day moving average

$9.86

Short ratio

10.26

Short %

24.87%

Management effectiveness

ROE (TTM)

192.31%

ROA (TTM)

31.14%

Profit margin

140.97%

Gross profit margin

$2.9M

Operating margin

87.29%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

17.40%

Share stats

Outstanding Shares

117M

Float

85.8M

Insiders %

2.15%

Institutions %

113.66%

Analyst Insights & forecasts

86% Buy

14% Hold

0% Sell

Based on information from 7 analysts.

Average price target

$19.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.72

-$0.77

6.49%

Q4 • 23Beat

-$0.32

-$0.73

56.16%

Q1 • 24Beat

-$0.42

-$0.52

19.23%

Q2 • 24Beat

-$0.33

-$0.42

21.43%

Q3 • 24Beat

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$30.9M

$-52.3M

169.59%

Q2 • 24

$44.8M

$-41.5M

92.81%

Q3 • 24

45.04%

20.63%

45.27%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$445M

$258M

58.08%

Q2 • 24

$437M

$281M

64.18%

Q3 • 24

1.66%

8.66%

10.50%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-45.1M

$-62.1M

$1.5M

$-45.1M

Q2 • 24

$-34.7M

$84.8M

$0.4M

$-34.8M

Q3 • 24

23.12%

236.44%

72.92%

22.80%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Extreme greed

+1.5

1.00

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Arcutis Biotherapeutics Inc share?

Arcutis Biotherapeutics Inc shares are currently traded for $15.19 per share.

How many shares does Arcutis Biotherapeutics Inc have?

Arcutis Biotherapeutics Inc currently has 117M shares.

Does Arcutis Biotherapeutics Inc pay dividends?

No, Arcutis Biotherapeutics Inc doesn't pay dividends.

What is Arcutis Biotherapeutics Inc 52 week high?

Arcutis Biotherapeutics Inc 52 week high is $15.79.

What is Arcutis Biotherapeutics Inc 52 week low?

Arcutis Biotherapeutics Inc 52 week low is $2.99.

What is the 200-day moving average of Arcutis Biotherapeutics Inc?

Arcutis Biotherapeutics Inc 200-day moving average is $9.86.

Who is Arcutis Biotherapeutics Inc CEO?

The CEO of Arcutis Biotherapeutics Inc is Todd Franklin Watanabe M.A..

How many employees Arcutis Biotherapeutics Inc has?

Arcutis Biotherapeutics Inc has 296 employees.

What is the market cap of Arcutis Biotherapeutics Inc?

The market cap of Arcutis Biotherapeutics Inc is $1.75B.

What is the P/E of Arcutis Biotherapeutics Inc?

The current P/E of Arcutis Biotherapeutics Inc is null.

What is the EPS of Arcutis Biotherapeutics Inc?

The EPS of Arcutis Biotherapeutics Inc is -$1.67.

What is the PEG Ratio of Arcutis Biotherapeutics Inc?

The PEG Ration of Arcutis Biotherapeutics Inc is null.

What do analysts say about Arcutis Biotherapeutics Inc?

According to the analysts Arcutis Biotherapeutics Inc is considered a buy.

Arcutis Biotherapeutics Inc news

thumbs_up_down

•Neutral

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 44,000 restricted stock units of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of December 2, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire•06 Dec 2024, 21:00

thumb_up_alt

•Positive

Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy?

Arcutis Biotherapeutics, Inc. (ARQT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARQT's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Zacks Investment Research•27 Nov 2024, 16:01

thumb_up_alt

•Positive

Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect?

The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 60.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research•27 Nov 2024, 16:00